In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.
|Videos|September 18, 2017
CON: Treatment Intensification in Poor Prognosis Germ Cell Tumors
Author(s)George J. Bosl, MD
In this video, Dr. Bosl argues against treatment intensification for poor-prognosis germ cell tumor patients who display unfavorable marker decline.
Advertisement
In this video, George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, New York, argues against treatment intensification for poor-prognosis germ cell tumor patients who display unfavorable marker decline.
Bosl gave a presentation on this topic earlier this year at the 2017 Genitourinary Cancers Symposium in Orlando, Florida.
Advertisement
Related to this article
Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.
Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.
Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.
![“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800.jpg?w=350&fit=crop&auto=format)
“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
2
How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?
3
FDA OKs Pirtobrutinib in Frontline CLL/SLL
4
How Is Subcutaneous Administration Changing Oncology Care Delivery?
5